🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

48 results for “Allogene” Clear

  1. Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets

    Mundipharma GmbH

    Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)

    phase 3 small molecule active

    1 trial

  2. PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  3. Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  4. -

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Cytomegalovirus infection post allogeneic allogeneic HLA-identical familial PHT

    phase 2 small molecule active

    1 trial

  5. ALLO-501A

    Allogene Therapeutics

    Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

    phase 2 gene therapy active

    1 trial

  6. ALLO-605

    Allogene Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 2 gene therapy terminated

    1 trial

  7. ALLO-647

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 2 mab terminated

    1 trial

  8. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  9. Adult Allogeneic Mesenchymal cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Acute Graft Versus Host Disease

    phase 2 small molecule completed

    1 trial

  10. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  11. Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    2 trials

  12. Allogeneic MSC (AlloMSC)

    China SXT Pharmaceuticals

    Refractory Systemic Lupus Erythematosus

    phase 2 mab active

    1 trial

  13. Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Adults diagnosed with SJS-TEN with at least 10% of body surface area involved

    phase 2 small molecule active

    1 trial

  14. Allogeneic NK Cells

    Artiva Biotherapeutics

    Refractory Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  15. CAP-1002 Allogeneic Cardiosphere-Derived Cells

    CAPRICOR THERAPEUTICS, INC.

    Myocardial Infarction

    phase 2 mab terminated

    1 trial

  16. Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie

    China SXT Pharmaceuticals

    CML,Blast Phase

    phase 2 small molecule active

    1 trial

  17. Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Astra Zeneca AB

    Recipients of allogeneic stem cell transplantation

    phase 2 small molecule active

    1 trial

  18. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  19. MSCAT-THAC Placebo, Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Systemic sclerosis

    phase 2 small molecule active

    1 trial

  20. Rixathon 100 mg concentrate for solution for infusion, Aplo-TCSE TCRaß+CD19+ depleto, Allogeneic peripheral blood-derived NK cells CD3- CD56+, Qarziba 4.5 mg/mL concentrate for solution for infusion, Melfalan Tillomed 50 mg polvere e solvente per soluzione iniettabile/infusione, TEPADINA 100 mg powder for concentrate for solution for infusion, Fludarabina Accord 25 mg/ml Concentrato per soluzione iniettabile o per infusione, Grafalon 20 mg/ml concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.

    phase 2 small molecule active

    1 trial

  21. SARCLISA 20mg/mL concentrate for solution for infusion.

    Pari Pharma GmbH

    Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation

    phase 2 small molecule active

    1 trial

  22. VEN+AZA+Modified BUCY

    First Tracks Biotherapeutics

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 2 small molecule active

    2 trials

  23. Vedolizumab

    Takeda Pharmaceuticals International AG

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 2 small molecule completed

    2 trials

  24. allogeneic human mesenchymal stem cells (hMSCs)

    United Therapeutics Europe Ltd

    Non-ischemic Dilated Cardiomyopathy

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources